Search research articles
Contact Us
Filters
Showing results (151-160 of 302) with videos related to
Page
of 31
Sort By:
Cancer Chemotherapy and Pharmacology
|
May 13, 2010
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination
Ramesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, et al.
Cureus
|
December 29, 2025
A Brief Report on Outcomes of Metastatic Non-Small Cell Lung Cancer: A Retrospective Observational Study in a Community Practice Setting
Brandon Poppe, Melissa S Kovacs, Neel Dharia, et al.
Journal of Gastrointestinal Oncology
|
June 11, 2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Werner Scheithauer, Ramesh K Ramanathan, Malcolm Moore, et al.
American Journal of Clinical Oncology
|
December 4, 2004
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma
Cathy Eng, Ramesh K Ramanathan, Ramesh K Ramathan, et al.
Targeted Oncology
|
October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2015
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
David Goldstein, Daniel D Von Hoff, Malcolm Moore, et al.
Investigational New Drugs
|
April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
Glen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Targeted Oncology
|
April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2006
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
August 25, 2011
Allometric scaling of pegylated liposomal anticancer drugs
Whitney P Caron, Harvey Clewell, Robert Dedrick, et al.
Page
of 31
Search research articles
Search
Showing results (151-160 of 302) with videos related to
Sort By:
Page
of 31
Cancer Chemotherapy and Pharmacology
|
May 13, 2010
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination
Ramesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, et al.
Cureus
|
December 29, 2025
A Brief Report on Outcomes of Metastatic Non-Small Cell Lung Cancer: A Retrospective Observational Study in a Community Practice Setting
Brandon Poppe, Melissa S Kovacs, Neel Dharia, et al.
Journal of Gastrointestinal Oncology
|
June 11, 2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Werner Scheithauer, Ramesh K Ramanathan, Malcolm Moore, et al.
American Journal of Clinical Oncology
|
December 4, 2004
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma
Cathy Eng, Ramesh K Ramanathan, Ramesh K Ramathan, et al.
Targeted Oncology
|
October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2015
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
David Goldstein, Daniel D Von Hoff, Malcolm Moore, et al.
Investigational New Drugs
|
April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
Glen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Targeted Oncology
|
April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2006
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
August 25, 2011
Allometric scaling of pegylated liposomal anticancer drugs
Whitney P Caron, Harvey Clewell, Robert Dedrick, et al.
Page
of 31